Research programme: fibroblast growth factor receptor antibodies - MorphoSys/ProChon Biotech

Drug Profile

Research programme: fibroblast growth factor receptor antibodies - MorphoSys/ProChon Biotech

Alternative Names: Anti-FGFR-3 antibodies; FGFR-3 antibodies; Fibroblast growth factor receptor HuCAL antibody research programme - MorphoSys/ProChon Biotech

Latest Information Update: 27 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; ProChon Biotech
  • Class Antibodies
  • Mechanism of Action Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Dwarfism; Musculoskeletal disorders

Most Recent Events

  • 16 May 2011 ProChon Biotech has been acquired by Histogenics Corporation
  • 27 Jun 2003 This compound is still in active development
  • 30 Jan 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top